MPM.L Regulatory News (MPM)

21 Feb 2005 12:13

RII PLC21 February 2005 February 21 2005 RII plc ("the company")Result of EGM RII shareholders approve EGM resolutions Shareholders in RII plc today approved all the resolutions for the company toraise £3.0million, to acquire BioPartners Limited ("BioPartners") and to changethe name of the company to Minster Pharmaceuticals plc (Minster). Application has been made to the London Stock Exchange for the resultantenlarged share capital to be admitted to trading on AIM and dealings areexpected to commence on Friday, 25th February 2005. Minster is developing compounds for the treatment and prevention of migraine andfor the treatment of chronic schizophrenia. Paul Sharpe, who has been appointed Chairman and Chief Executive of Minster,said: " We are in a strong position to address the very large markets that existfor migraine and for schizophrenia and so to generate value for our shareholdersas we move our compounds closer towards clinical use." Robert Stubbs, who is stepping down as Chairman of the Company but continuing asa non-executive director, said: "We are delighted to have acquired BioPartnersand thank our shareholders for their support. We look forward to the future withconfidence" ENDS For further information, please contact Cubitt ConsultingMichael Henman020 7367 5106 Minster Pharmaceuticals plcDr Paul SharpeChairman/CEO01799 506623 Minster Pharmaceuticals plcRobert StubbsDirector020 7355 4071 Insinger de BeaufortJeremy KingStephen Goschalk020 7190 7000 This information is provided by RNS The company news service from the London Stock Exchange